Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating a drug called BT8009 alone and in combination with
nivolumab in participants with advanced solid tumors associated with Nectin-4 expression or
in participants with advanced solid tumor malignancies having renal insufficiency.
The main goals of this study are to:
- Find the recommended dose of BT8009 that can be given safely to participants alone and
in combination with nivolumab
- Learn more about the side effects and effectiveness of BT8009 alone and in combination
with nivolumab
- Learn more about BT8009 alone and in combination with nivolumab
- Learn more about BT8009 alone in patients with kidney disease